Cargando…

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this efficacy appears enhanced in combination with conven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395112/ https://www.ncbi.nlm.nih.gov/pubmed/28034990 http://dx.doi.org/10.3324/haematol.2016.158394

Ejemplares similares

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
por: Pitts, Todd M., et al.
Publicado: (2016)

Aurora A inhibition limits centrosome clustering and promotes mitotic catastrophe in cells with supernumerary centrosomes
por: Navarro-Serer, Bernat, et al.
Publicado: (2019)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
por: Niu, Huifeng, et al.
Publicado: (2015)

Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling
por: Shang, Yuan-Yuan, et al.
Publicado: (2017)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
por: Niu, Huifeng, et al.
Publicado: (2017)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
por: Goldberg, Stuart L., et al.
Publicado: (2014)

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells
por: Yuan, Chun-Xiu, et al.
Publicado: (2015)

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
por: Ding, Yong-Hui, et al.
Publicado: (2015)

Inhibition of Aurora Kinase A by Alisertib Reduces Cell Proliferation and Induces Apoptosis and Autophagy in HuH-6 Human Hepatoblastoma Cells
por: Tan, Jingyi, et al.
Publicado: (2020)

Sustained and durable response with Alisertib monotherapy in the treatment of relapsed Atypical Teratoid Rhabdoid Tumor (ATRT)
por: Howden, Kaitlyn, et al.
Publicado: (2022)

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
por: Nguyen, Rosa, et al.
Publicado: (2022)

Health behaviours and beliefs in individuals with familial pancreatic cancer
por: Underhill-Blazey, Meghan, et al.
Publicado: (2019)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
por: Gay, Carl M., et al.
Publicado: (2020)

A state‐wide initiative to promote genetic testing in an underserved population
por: Underhill, Meghan L., et al.
Publicado: (2017)

Proinflammatory Cytokines and Chemokines at the Skin Interface during Powassan Virus Transmission
por: Hermance, Meghan E, et al.
Publicado: (2014)

Tick Saliva Enhances Powassan Virus Transmission to the Host, Influencing Its Dissemination and the Course of Disease
por: Hermance, Meghan E., et al.
Publicado: (2015)

Tick–Virus–Host Interactions at the Cutaneous Interface: The Nidus of Flavivirus Transmission
por: Hermance, Meghan E., et al.
Publicado: (2018)

Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America
por: Hermance, Meghan E., et al.
Publicado: (2017)

Utilization of RNA in situ Hybridization to Understand the Cellular Localization of Powassan Virus RNA at the Tick-Virus-Host Interface
por: Hermance, Meghan E., et al.
Publicado: (2020)

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities
por: Weinberg, Olga K., et al.
Publicado: (2018)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway
por: Hao, Jianwen, et al.
Publicado: (2021)

Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer
por: Zhang, Xiaoqiang, et al.
Publicado: (2023)

Alisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
por: Ren, Baojun, et al.
Publicado: (2023)

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
por: Haddad, Tufia C., et al.
Publicado: (2023)

Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment
por: Hong, Fangxin, et al.
Publicado: (2016)

Transovarial Transmission of Heartland Virus by Invasive Asian Longhorned Ticks under Laboratory Conditions
por: Raney, Wilson R., et al.
Publicado: (2022)

Impact of Electronic Self-Assessment and Self-Care Technology on Adherence to Clinician Recommendations and Self-Management Activity for Cancer Treatment–Related Symptoms: Secondary Analysis of a Randomized Controlled Trial
por: Knoerl, Robert, et al.
Publicado: (2019)

Acute Effects of a Thermogenic Drink on Energy Expenditure
por: Mah, Eunice, et al.
Publicado: (2022)

The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G(2)/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells
por: Li, Jin-Ping, et al.
Publicado: (2015)

RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping
por: Zamalloa, Luis Gregory, et al.
Publicado: (2023)

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
por: O’Connor, Owen A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_457a2jg017jo01u1rebgdd9uf7